Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Ian Brotherick.

Newcastle AuthorsTitleYearFull text
Seb Aspinall
Susan Stamp
Dr Ian Brotherick
Dr Brian Shenton
Andrew Griffiths
et al.
A method of tumour androgen receptor expression in primary operable breast cancer measured by flow cytometry2002
Fiona Girdler
Dr Ian Brotherick
Professor Thomas Lennard
Dr James Young
Dr Brian Shenton
et al.
Changes in the expression of oestrogen receptors (ER alpha and ER beta) in the MCF7 cell line with endocrine treatments2002
Fiona Girdler
Dr Ian Brotherick
William Cunliffe
Professor Thomas Lennard
Dr Brian Shenton
et al.
ER alpha and ER alpha exon5 expression in tamoxifen treated tumours2002
Dr Ian Brotherick
Susan Stamp
William Cunliffe
Dr Gail Higginbottom
Dr James Young
et al.
Neoadjuvant tamoxifen treatment and its effect on MUC1 expression in primary breast cancer2002
Seb Aspinall
Dr David Cook
Dr Ian Brotherick
Andrew Griffiths
Clive Griffith
et al.
Serum adrenal androgens in women with primary operable breast cancer2002
Seb Aspinall
Dr Ian Brotherick
Dr David Cook
Dr Brian Shenton
Andrew Griffiths
et al.
Serum testosterone in women with primary operable breast cancer2002
Dr Ian Brotherick
Susan Stamp
Fiona Girdler
William Cunliffe
Professor Thomas Lennard
et al.
The influence of tamoxifen treatment on E-cadherin expression in primary breast cancer2002
Susan Stamp
Seb Aspinall
Dr Ian Brotherick
Dr Brian Shenton
Professor Thomas Lennard
et al.
The use of multiparameter flow cytometry to quantify the androgen receptor in primary breast cancer2002
Fiona Girdler
Dr Ian Brotherick
William Cunliffe
Professor Thomas Lennard
Dr James Young
et al.
Three weeks of tamoxifen treatment alters the expression of ER alpha, ER beta and pS22002
Fiona Girdler
Dr Ian Brotherick
Dr Brian Shenton
ARMS (TM) allele-specific amplification-based detection of mutant p53 DNA and mRNA in tumors of the breast2001
Fiona Girdler
Dr Ian Brotherick
Professor Thomas Lennard
Dr James Young
Dr Brian Shenton
et al.
Changes in the expression of oestrogen receptors (ER alpha and ER beta) in the MCF7 cell line with endocrine treatments.2001
Adillah Binti Yusof
Dr Ian Brotherick
William Cunliffe
Professor Thomas Lennard
Dr James Young
et al.
ER alpha and ER alpha Delta 5 expression in tamoxifen-treated breast tumours.2001
Dr Jonathan Hanson
Jagnohan Varma
Professor Adrian Allen
Dr Brian Shenton
Dr James Young
et al.
MUC1 expression in primary breast cancer: The effect of tamoxifen treatment2001
Dr Ian Brotherick
Fiona Girdler
Dr Brian Shenton
The variation in expression of cytokeratin phenotypes in primary breast cancer2001
Fiona Girdler
Dr Ian Brotherick
William Cunliffe
Professor Thomas Lennard
Dr James Young
et al.
Three weeks of tamoxifen treatment alters the expression of ER alpha, ER beta and pS2.2001
Fiona Girdler
Dr Brian Shenton
Dr James Young
Dr Ian Brotherick
Use of the monoclonal antibody DAKO-ERβ (8D5-1) to measure oestrogen receptor beta in breast cancer cells2001
Fiona Girdler
Dr Ian Brotherick
The oestrogen receptors (ERα and ERβ) and their role in breast cancer: A review2000
Dr Ian Brotherick
Dr Brian Shenton
Dr Brian Angus
Jagnohan Varma
Professor Frederick Campbell
et al.
Cyclin D3 expression, cell proliferation and pathological stage of human primary colorectal cancer1999
Dr Daya Karat
Dr Ian Brotherick
Dr Brian Shenton
Dr Debbie Scott
Professor Michael Griffin
et al.
Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study1999
Dr Ian Brotherick
Dr Brian Shenton
Ronald Wilson
Professor Frederick Campbell
Growth dysregulation and p53 accumulation in human primary colorectal cancer1999
Dr David Cook
Dr Ian Brotherick
Dr Brian Shenton
Emeritus Professor Colin Self
Lectin ELISA for the c-erb-B2 tumor marker protein p185 in patients with breast cancer and controls1999
Garrett Durkan
Dr Ian Brotherick
Kilian Mellon
The impact of transurethral resection of bladder tumour on serum levels of soluble E-cadherin1999
Dr Ian Brotherick
Professor Craig Robson
Dr Jonathan Shenfine
Michael White
William Cunliffe
et al.
Cytokeratin expression in breast cancer: Phenotypic changes associated with disease progression1998
Dr Ian Brotherick
Dr Brian Shenton
Professor Thomas Lennard

Are fine needle breast aspirates representative of the underlying solid tumor: a comparison on receptor levels, ploidy and the influence of cytokeratin gates

1995
Dr Ian Brotherick
Dr Brian Shenton
Dr William Cowan
Dr Brian Angus
Professor Thomas Lennard
et al.

P53 expression measured by flow cytometry: a comparison of 3 monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer

1995
Dr Ian Brotherick
Dr Brian Shenton
Dr Brian Angus
Ian Waite
Professor Thomas Lennard
et al.
A flow cytometric study of c-erbB-3 expression in breast cancer1995
Dr Ian Brotherick
Dr Brian Shenton
Dr William Cowan
Dr Brian Angus
Professor Thomas Lennard
et al.
Relationship between flow cytometric and immunohistochemically detected C-ERBB-2 expression, grade and DNA ploidy in breast cancer1995
Dr Ian Brotherick
Professor Thomas Lennard
Susan Cook
Dr Brian Shenton
Use of the biotinylated antibody dako-ER 1D5 to measure estrogen receptor on cytokeratin positive cells obtained from primary breast cancer cells1995
Dr Ian Brotherick
Professor Thomas Lennard
Susan Cook
Dr Brian Shenton
Flow cytometric method for the measurement of epidermal growth-factor receptor and comparison with the radio-ligand binding assay1994
Dr Ian Brotherick
Dr Brian Shenton
Professor John Kirby
Dr Jeremy Palmer
Emeritus Professor Steve Yeaman
et al.

Production of immunosuppressive factors by a cultured tumor cell line and their effect on lymphocyte proliferation and cells cycle response

1993
Dr Brian Shenton
Dr Ian Brotherick
Robert Taylor
Professor Thomas Lennard

Alterations in circulating lymphocyte number and function after circulation through colorectal carcinomas

1991